While the LifeMark transaction was the feature event of the year, the ongoing business model continued to  pay dividends for our shareholders. Eliminating the gains from the LifeMark transaction, the following  table gives a snapshot of the 2011 fiscal year:   2012  2010  2011 % Change  Run Rate  Revenue  16,657,034 21,497,960 29.1%  27,768,900 G&A  2,131,167 3,291,856 54.5%  3,200,000 Normalized EBITDA  12,710,076 16,112,725 26.8%  24,298,900 EBITDA Margin  76.3% 75.0% -1.8% 87.5% Debt  29,200,000 6,500,000 -77.7%  4,500,000 Basic Shares O/S  16,426,604 19,475,210 18.6%  Fully Diluted Shares O/S 16,974,318 20,034,604 18.0%  Dividends per share   $ 0.95  $ 1.04 10.1%   $ 1.14 Share Price   $ 11.60 $ 18.00 55.2%  Total Return  37.0% 64.1% Market Cap - Basic  190,548,606 350,553,780 84.0%  Market Cap - FD  196,902,089 360,622,872 83.1%  2011 In Review  The first half of 2011 was spent negotiating the LifeMark transaction and also sourcing, negotiating and  structuring new partnerships through which we would contribute the proceeds from LifeMark. In June  2011, Alaris received proceeds of $65 million for a reduction of our interest in LifeMark and disposition of  our interest in MediChair. Through the course of the next six months of 2011, Alaris contributed more  than $76 million in two new partnerships as well as a further contribution to a current partner. The net  result of those transactions was a significant increase in our distributable cash per share as well as a  dramatic change in the diversification of our revenue stream. The following chart gives an excellent look at  how our revenue stream has been diversified over the past twelve months: 2 2011 Annual Report  Alaris Royalty Corp.